This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical and Laboratory Studies on Thirty-Three Patients

THOMAS M. GOCKE, M.D.; HARVEY S. COLLINS, M.D.; MAXWELL FINLAND, M.D.

Arch Intern Med. 1949;84(6):857-874.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

AUREOMYCIN is an antibiotic which, from the results of early studies in vitro and in experimental infections, as well as in initial clinical trials, appears to have a wider range of activity than its successful antecedents, penicillin and streptomycin.¹ This range encompasses most of the known causative agents of the acute pneumonias, including the gram-positive and gram-negative bacteria, the organisms of the psittacosis-lymphogranuloma venereum group and the Q fever and other rickettsias. Since aureomycin was also found to be effective when given by mouth and was essentially free of serious toxic effects, it seemed particularly suitable for extended clinical trials in cases of pneumonias of diverse origin. During the past year an attempt was therefore made to evaluate the therapeutic effectiveness of aureomycin in the various types of pneumonia and in some of the other severe acute infections of the respiratory tract that were available for study. The present . . . [Full Text PDF of this Article]

Author Affiliations
Research Fellow in Medicine, Harvard Medical School, and Research Fellow, Thorndike Memorial Laboratory; Milton Fellow, Harvard Medical School, and Research Fellow, Thorndike Memorial Laboratory; Associate Professor of Medicine, Harvard Medical School; Chief, Fourth Medical Service and Associate Physician, Thorndike Memorial Laboratory, Boston City Hospital BOSTON

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital and the Department of Medicine, Harvard Medical School.

Footnotes
Aided by a grant from the United States Public Health Service.

The aureomycin was provided by the Lederle Laboratories, Division of American Cyanamid Company, Pearl River, N. Y.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?